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Mobility and activities of daily living
• Mobilise patients as early as possible after stroke (B).
• Physiotherapists should not limit their practice to one 
“approach” but should select interventions according to 
the patient’s individual needs (B).
• Where the aim of treatment is the immediate 
improvement of walking speed, walking efficiency, 
gait pattern, or weight bearing during stance, an 
appropriately qualified health professional should 
assess the patient’s suitability for ankle foot orthoses 
(A).
• Consider treadmill training to improve gait speed in 
people who are walking independently at the start of 
treatment (B).
• When the goal of treatment is to improve functional 
ambulation, offer gait oriented physical fitness training 
to all patients assessed as medically stable and 
functionally safe to participate (A).
• When the aim of treatment is to improve gait speed, 
walking distance, functional ambulation, or “sit to 
stand to sit,” include repetitive task training, where it is 
assessed to be safe and acceptable to the patient (B).
• Where considered safe, pursue every opportunity to 
increase the intensity of treatment for improving gait 
(B).
• Occupational therapists should include training in 
personal activities of daily living as part of an inpatient 
stroke rehabilitation programme (B).
• Splinting is not recommended for improving upper limb 
function because it does not prevent the development 
of contractures or improve muscle extensibility (B).
Assessment of nutritional status and continence
• Include ongoing monitoring of nutritional status 
with the following parameters (D):
- Swallowing status
- Nutritional intake
- Feeding assessment and dependence
- Unintentional weight loss
- Biochemical measures (low prealbumin, 
impaired glucose metabolism).
• Every service caring for patients with stroke 
should develop and adhere to local urinary and 
faecal continence guidelines, including advice on 
appropriate referral (GPP).
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.1 Despite 
considerable advances in organised stroke care over recent 
years, improvements are still needed,2 because patients 
have been reported to spend up to 50% of their time in 
bed3 and only 20% of their time in treatment.4 Since pub-
lication of the previous Scottish Intercollegiate Guide-
lines Network (SIGN) guideline on rehabilitation after 
stroke (SIGN 64), several small studies have shown the 
effectiveness of new therapeutic techniques and technolo-
gies.5 This guideline supersedes the earlier guideline and 
summarises the most recent recommendations from SIGN 
on rehabilitation after stroke.6 It also complements SIGN 
guidelines 119 and 108 on other aspects of the manage-
ment of stroke.7 8 
Recommendations
SIGN recommendations are based on systematic reviews 
of best available evidence. The strength of the evidence is 
graded as A, B, C, or D (figure), but the grading does not 
reflect the clinical importance of the recommendations. Rec-
ommended best practice (“good practice points”), based on 
the clinical experience of the guideline development group, 
is also indicated (as GPP).
Arranging appropriate care
• Admit stroke patients who require admission to 
hospital to a stroke unit staffed by a coordinated 
multidisciplinary team with a special interest in stroke 
care (A).
• In exceptional circumstances, when admission to a 
stroke unit is not possible, provide rehabilitation in a 
generic rehabilitation ward on an individual basis (B).
• The core multidisciplinary team should include 
appropriate levels of nursing, medical, physiotherapy, 
occupational therapy, speech and language therapy, 
and social work staff (B).
• Stroke inpatients should be treated 24 hours a day 
by nurses who specialise in stroke and are based in a 
stroke unit (B).
• Actively involve patients and carers early in the 
rehabilitation process (A) and routinely provide them 
with information using active information strategies, 
which include a mixture of education and counselling 
techniques (A).
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scale)12 and treat appropriately as soon as possible 
(GPP).
• In patients with central post-stroke pain that does 
not respond to standard treatment, and where 
clinician and patient are aware of potential side 
effects, consider the use of amitriptyline (titrated 
to a dose of 75 mg). If amitriptyline is ineffective or 
contraindicated, lamotrigine or carbamazepine are 
alternatives, although they have a high incidence of 
side effects (B).13
• Given the complexity of post-stroke shoulder pain, 
consider the use of algorithms or an integrated care 
pathway for its diagnosis and management (GPP).
Shoulder subluxation
• Consider electrical stimulation to the 
supraspinatus and deltoid as soon as possible 
after stroke in patients at risk of developing 
shoulder subluxation from having little or no 
activity in shoulder muscles (A).
Transfer from hospital to home
• Patients with mild to moderate stroke should be able 
to access stroke specialist early supported discharge 
services in addition to conventional organised stroke 
inpatient services (A).
• Health boards should consider providing a specific 
local expert therapist to advise rehabilitation 
teams on subjects such as providing information 
on relevant statutory services such as disability 
employment advisers at job centres, organisations 
that provide opportunities for people with 
disabilities (such as Momentum), or voluntary 
services that can provide help and support (such 
as Chest Heart and Stroke Scotland (CHSS) and the 
Stroke Association (GPP)).
living in the community
• Ask patients about vocational activities, initiate 
liaison with employers early in the rehabilitation 
pathway, and assess the patient’s ability to meet the 
needs of current or potential employment (GPP).
• Advise patients that they must not drive for at least 
one month after their stroke (GPP).
• If there is doubt about a patient’s ability to drive, 
refer the patient to the local Disabled Drivers’ 
Assessment Centre (www.dft.gov.uk/dvla) (D).
Overcoming barriers
Specialist rehabilitation is central to successful recovery 
after stroke and specific standards and targets to drive 
improvements must be implemented. The evidence base 
for rehabilitation interventions is expanding, and it chal-
lenges traditional patterns of care in many areas. Stroke 
rehabilitation teams need to adopt these evidence based 
changes and translate them into routine clinical practice. 
Patients should receive treatment seven days a week, and 
increasing the use of generic therapy assistants across 
rehabilitation disciplines may help achieve this. Moving 
rehabilitation from hospital to home at an earlier stage 
improves outcomes but will need further development 
Cognitive and emotional assessment
• Fully assess for cognitive strengths and weaknesses 
when undergoing rehabilitation or when returning 
to cognitively demanding activities such as driving 
or work (GPP).
• Occupational therapists with expertise in 
neurological care may carry out cognitive 
assessment, although some patients with more 
complex needs should be referred for specialist 
neuropsychological expertise (GPP).
• Screen all stroke patients for visual problems and 
refer appropriately (C).
• Consider appropriate referral to health and clinical 
psychology services for patients and carers to 
promote good recovery and adaptation and to 
prevent and treat abnormal adaptation to the 
consequences of stroke (GPP).
• Screen all stroke patients for mood disturbance as 
early as possible using a validated tool, such as the 
stroke aphasic depression questionnaire (SAD-Q)9 or 
general health questionnaire of 12 items (GHQ-12)10 
(GGP).
• Screen patients with post-stroke fatigue for 
depression (GPP).
• Consider patients with post-stroke depression for 
treatment with antidepressants (A).11
• Choose the appropriate antidepressant on an 
individual basis (GPP).
Pain assessment
• Ask patients about pain and assess the severity of 
pain (using a validated pain assessment tool such 
as the visual analogue scale or numerical rating 
Explanation of SIGN grades of recommendations
• At least one high quality meta-analysis, systematic review of randomised controlled trials, or 
randomised controlled trial with a very low risk of bias and directly applicable to the target 
population; or
• A body of evidence consisting principally of well conducted meta-analyses, systematic 
reviews of randomised controlled trials, or randomised controlled trials with a low risk of bias 
directly applicable to the target population, and demonstrating overall consistency of results
The grade of recommendation relates to the strength of the supporting evidence on which 
the evidence is based. It does not reflect the clinical importance of the recommendation
A
• A body of evidence including studies rated as high quality systematic reviews of case-control 
or cohort studies, and high quality case-control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relation is causal and that are directly 
applicable to the target population, and with overall consistency of results; or
• Extrapolated evidence from studies described in A
B
• A body of evidence including well conducted case-control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relation is causal and that are directly 
applicable to the target population and with overall consistency of results; or
• Extrapolated evidence from studies described in B
C
• Non-analytic studies, such as case reports, case series, expert opinion;  or
• Extrapolated evidence from studies described in C
D
Recommended best practice based on the clinical experience of the guideline development 
group
Good Practice Points (GPP)
1358   BMJ | 19 June 2010 | VoluMe 340
PRACTICE
of early supported discharge teams with specialist stroke 
skills.14 Recovery often continues at a slower rate for 
many years after stroke. It is important to maintain access 
to rehabilitation services throughout this time, and the 
use of local leisure centres to facilitate ongoing exercise 
programmes should be encouraged.15 Finally, despite 
the best medical care, around 20% of stroke patients die 
within the first 30 days.16 The provision of high quality 
palliative care by stroke teams to these patients and their 
families is an area that requires further development.
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The effects of dihydropyridine calcium 
antagonists may delay the diagnosis of 
primary hyperaldosteronism
About 5-13% of patients with hypertension have primary 
hyperaldosteronism,1-4 defined as autonomous production 
of aldosterone, which leads to excessive retention of sodium 
plus water and resistant hypertension. It is important to 
identify such patients because they have a higher morbid-
ity and mortality from cardiovascular disease than age and 
sex matched patients with essential hypertension.2 In addi-
tion, surgery can significantly improve long term outcomes 
in such patients.5
With improved management of hypertension and greater 
awareness of primary hyperaldosteronism, more investiga-
tions are being performed in patients taking antihypertensive 
agents. Dihydropyridine calcium antagonists increase renin 
production and reduce aldosterone, thereby reducing the 
aldosterone:renin ratio—the initial test for primary hyperal-
dosteronism.6 However, these effects are underappreciated,7 
with recent publications reporting insignificant effects on the 
aldosterone:renin ratio.8-12 We describe three patients who 
were initially misclassified as having essential hypertension 
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because of repeatedly unremarkable aldosterone:renin ratios 
while taking dihydropyridine calcium antagonists.
Case reports
Between 2003 and 2008, three patients were diagnosed 
with biochemically confirmed primary hyperaldosteronism 
caused by autonomous aldosterone producing adeno-
mata. All three had initially been misclassified because of 
repeatedly unremarkable aldosterone:renin ratios while 
taking dihydropyridine calcium antagonists. They had 
otherwise been appropriately investigated—other inter-
fering  antihypertensive drugs had been withdrawn and 
plasma potassium had been carefully corrected.  Diagnosis 
was finally confirmed by repeatedly raised ambulatory 
aldosterone:renin ratios after calcium antagonist with-
drawal. All three patients underwent adrenal vein sampling, 
which confirmed lateralisation of aldosterone secretion, and 
two patients proceeded to laparoscopic adrenalectomy.
Case 1
A 56 year old man presented with a 15 year history of resistant 
hypertension; he had initially been treated with amlodipine 
10 mg daily with subsequent addition of  lisinopril 10 mg 
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mia requiring transient administration of oral potassium. 
She had been started on amlodipine 5 mg daily. She had 
also been surgically treated for primary hyperparathy-
roidism after resection of a solitary chief cell adenoma in 
2004. Aldosterone:renin ratios measured over 10 years 
were all below the diagnostic limit for primary hyperal-
dosteronism, but after amlodipine was withdrawn and 
prazosin started at 1 mg twice daily, ratios increased above 
this limit (table  1). Lateralisation of aldosterone secre-
tion to the right adrenal gland was confirmed by adrenal 
vein  sampling (table 2) and computed tomography of the 
 abdomen showed a 9 mm  dominant right adrenal nod-
ule. After careful  consideration of the options, the patient 
declined surgery. She was restarted on amlodipine 5 mg 
daily and advised on lifestyle  modification. Recent blood 
pressure measurement was 125/80 mm Hg on  treatment.
Case 3
A 44 year old woman developed hypertension 10 months 
before referral, with episodes of severe recurrent hypokalae-
mia needing large oral doses, up to 6.6 g, of potassium; she 
was treated with felodipine 15 mg daily. She had no relevant 
medical history. Multiple aldosterone:renin ratios had been 
performed over the preceding 10 months, with all results 
below the decision limit for primary hyperaldosteronism. 
After felodipine was withdrawn and prazosin started at 1 
mg twice daily, aldosterone:renin ratios increased above the 
limit consistent with primary hyperaldosteronism (table 1). 
Lateralisation of aldosterone secretion to the right adrenal 
gland was confirmed by adrenal vein sampling (table 2), 
and computed tomography of the abdomen showed a 2.5 
cm right adrenal nodule. Elective laparoscopic right adrena-
lectomy and histology confirmed a solitary adenoma. She 
remains normotensive and normokalaemic without the need 
for antihypertensive drugs or potassium supplements.
discussion
All three patients with biochemically proven and adrenal 
venous sampling confirmed unilateral aldosterone produc-
tion were initially diagnosed with essential hypertension. 
After withdrawal of dihydropyridine calcium antagonists and 
repeated measurement of the aldosterone:renin ratio over 
four weeks, the diagnosis of primary  hyperaldosteronism 
was confirmed. Current recommended first line drugs for 
essential hypertension include calcium antagonists,  singly 
or in combination.5 14 15 Around 17% of treated patients with 
hypertension receive a calcium antagonist,7 so patients may 
often be investigated for secondary hypertension while 
 taking  dihydropyridine calcium antagonists.
Ambulatory assessment of the aldosterone:renin ratio is 
the most reliable and accessible way to screen for  primary 
hyperaldosteronism. Many studies have shown that this 
ratio is superior to isolated potassium or aldosterone meas-
urements (both have lower sensitivity) or a single renin 
measurement (which is less specific).16 It is prudent to take 
note of individual renin and aldosterone results, however, 
because a low or suppressed renin may be caused by pri-
mary hyperaldosteronism or low renin hypertension even 
when the aldosterone:renin ratio is unremarkable. But in our 
three patients, renin was not suppressed initially, and indi-
vidual aldosterone and renin values were within  appropriate 
daily. He developed severe hypokalaemia, requiring up to 
4.8 g of oral potassium daily to maintain normokalaemia. 
Spot urinary potassium was 44 mmol/l after withholding 
supplements for 24 hours, indicating severe, inappropri-
ate urinary potassium wasting. Multiple aldosterone:renin 
ratios obtained while taking the above antihypertensive 
agents were interpreted as inconsistent with primary hyper-
aldosteronism. Lisinopril was stopped because of side effects. 
After stopping amlodipine and starting prazosin 1 mg twice 
daily, aldosterone:renin ratios were repeatedly above the 
limit for a diagnosis of primary hyperaldosteronism (table 
1). Lateralisation of aldosterone production to the right adre-
nal gland was confirmed by adrenal vein sampling (table 2), 
which showed a raised unilateral aldosterone:cortisol ratio 
and suppressed contralateral ratio.13 Elective right adrenalec-
tomy was performed and histology showed multiple adreno-
cortical micronodules. Postoperatively, his aldosterone:renin 
ratio normalised, hypokalaemia resolved without potassium 
supplements, and blood pressure improved.
Case 2
A 58 year old woman developed hypertension in her mid-
30s, after having intermittent episodes of mild hypokalae-
Table 1 | Concentrations of aldosterone and renin and aldosterone:renin ratios before, 2 weeks, 
and 4 weeks after patients stopped taking dihydropyridine calcium antagonists
Scenario Renin (mU/l)* Aldosterone (nmol/l)† Ratio‡ 
Case 1
On calcium antagonist 23.7 0.310 0.013
2 weeks after stopping 1.4 0.129 0.092
4 weeks after stopping 3 0.627 0.209
Postoperatively 23.7 0.310 0.013
7.2 0.110 0.015
Case 2
On calcium antagonist 10.7 0.497 0.046
2 weeks after stopping 7.4 0.547 0.074
4 weeks after stopping 3 0.643 0.214
Case 3
On calcium antagonist 12.2 0.333 0.027
2 weeks after stopping 8.5 0.642 0.076
4 weeks after stopping 7.9 1.051 0.133
Postoperatively 17 0.126 0.007
*Renin ambulatory reference interval 7 to 50 mU/l; 1 pg/ml=1.67 mIU/l. 
†Aldosterone ambulatory reference interval 0.08 to 0.80 nmol/l.
‡Reference interval <0.05.
Table 2 | Results of adrenal venous sampling












1 Right multiple 
adrenocortical 
micronodules†
RAV 213 14 900 0.014
LAV 3.46 4230 0.0008
IVC 1.46 670 0.0022
2 Right 9mm nodule‡ RAV 10 .7 1860 0.0057
LAV 1.23 884 0.0014
IVC 0.478 104 0.0046
3 Right 24 mm nodule‡ RAV 8.43 610 0.0138
LAV 0.967 1900 0.0005
IVC 0.414 630 0.0007
*IVC=inferior vena cava, LAV=left adrenal vein, RAV=right adrenal vein.
†On histology.
‡On computed tomography.
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ambulatory reference intervals. Two of the three patients had 
severe, inappropriate renal potassium wasting, however, 
so in the setting of hypertension the index of suspicion for 
primary hyperaldosteronism was high. The other patient 
was normokalaemic, but a revised diagnosis was pursued 
because of coexistant endocrinopathy. Other patients who 
are normokalaemic, with no other pre-existing endocrinopa-
thies, and who are taking dihydropyridine calcium antago-
nists could consequently be misdiagnosed.
Dihydropyridine calcium antagonists alter the 
aldosterone:renin ratio by competitively blocking the L 
type calcium channel, inhibiting calcium influx, and low-
ering aldosterone secretion.17 18 Aldosterone suppression 
results in higher plasma renin concentrations, compound-
ing the effect of these antagonists on interpretation of the 
aldosterone:renin ratio. Within two weeks of withdrawal of 
calcium channel antagonists, serum aldosterone increased, 
plasma renin decreased, and the aldosterone:renin ratio 
became diagnostic of primary hyperaldosteronism in all 
three cases.
It is recommended that confounding drugs are with-
drawn for one to two weeks before testing.8 16 19 Although 
the aldosterone:renin ratio continued to rise after two weeks, 
all our patients had a positive diagnostic ratio within two 
weeks of stopping treatment.
Adrenal vein sampling was performed in all three cases 
after carefully counselling the patients about the risks and 
limitations of the procedure and ascertaining their willing-
ness to have surgery in the event of lateralised aldosterone 
production. The current treatment for a lateralising single 
aldosterone producing tumour is laparoscopic adrenalec-
tomy, which is considered curative. Bilateral aldosterone 
secretion can be successfully treated by the addition of 
aldosterone blocking agents, such as spironolactone.10 20
We describe a series of patients with unilateral, adrenal 
venous sampling confirmed, primary hyperaldosteronism, 
whose diagnosis was delayed by the affects of dihydropyri-
dine calcium antagonists on initial aldosterone:renin ratio 
assessments. Doctors should be aware of this phenomenon 
and consider repeat assessment after drug withdrawal even 
in patients who are normokalaemic at presentation.
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One may remember a time when mobile phones 
were not ubiquitous, and the only people who felt it 
necessary to use them regularly were stockbrokers 
and drug dealers. With rose tinted spectacles, we 
recall a time when you would call an acquaintance 
and if he or she did not answer you would leave a 
message or call back later. It seems that the ubiquity 
of the mobile phone has been accompanied by an 
irrepressible need to be contactable at all times.
While we were operating on a man under a regional 
block to his arm a mobile phone started ringing in the 
operating theatre. To our astonishment, the patient 
retrieved his mobile phone from his undergarments 
and, while brandishing it with his mobile hand, 
asked whether he would be able to take the call. 
We wonder what other essential or important 
activities the modern man or woman would be willing 
to interrupt to take a call on their mobile phone? A 
funeral, their own wedding, child birth?
“Sorry darling, can’t talk right now I’m just burying 
my father/tying the knot/trying to deliver a placenta.”
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